載入...
When to Consider Immune Checkpoint Inhibitors in Oncogene-Driven Non-Small Cell Lung Cancer?
Targeted therapies and more recently immune checkpoint inhibitors (ICI) have transformed the treatment landscape of advanced NSCLC. Clinical trials investigating immune checkpoint inhibitors (ICI) have usually excluded patients with oncogenic drivers, so that the outcome of these agents in this popu...
Na minha lista:
| 發表在: | Curr Treat Options Oncol |
|---|---|
| Main Authors: | , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Springer US
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6554237/ https://ncbi.nlm.nih.gov/pubmed/31172347 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11864-019-0652-3 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|